You are here

New Compound Gets Orphan Drug Status for Huntington’s Disease

MP-101 Has Potential to Drastically Alter Disease Progression

Mitochon Pharmaceuticals’ MP-101 has received an orphan drug designation from the FDA for the treatment of Huntington’s disease. The company said that MP-101–a mitochondrial targeted compound–has been shown to protect both spiny neurons and general neurons and minimize brain-volume loss in patients with Huntington’s disease. Combined, these effects could significantly alter the disease’s progression in patients.

MP101 and MP201 are mitochondrial targeted, once-a-day, oral therapies that safeguard cells from the damage caused by numerous degenerative processes. In preclinical studies, both compounds showed significant protective and functional benefits in disease models. These include brain-volume sparing in Huntington’s disease; protection from demyelination in multiple sclerosis; and preserving dopamine neurons in Parkinson’s disease.

Mitochon will be initiating phase 1 studies in normal healthy volunteers this year and phase 2 studies are expected to take place in 2020.

Source: Biospace, March 5, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage